OvaScienceSM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will participate in the Partnering for Cures meeting, an event convened by the Milken Institute’s FasterCures. OvaScience will be part of a panel titled, “Collaborative Capital,” on November 18, 2014 at 11:00 a.m. ET at the Grand Hyatt New York. Partnering for Cures brings together decision-makers from across diseases and all sectors of medical research to foster collaborations needed to speed up and improve outcomes-driven research and development.
About OvaScience
OvaScience (NASDAQ: OVAS) is a global life
sciences company dedicated to improving fertility for women around the
world. OvaScience is discovering, developing and commercializing new
fertility treatments because we believe women deserve more options. Each
OvaScience treatment is based on the Company’s proprietary technology
platform that leverages the breakthrough discovery of egg precursor
(EggPCSM) cells – immature egg cells found inside the
protective ovarian lining. The AUGMENTSM treatment, a
fertility option specifically designed to improve egg health, is
available in certain IVF clinics in select international regions.
OvaScience is developing the OvaPrimeSM treatment, which
could expand a woman’s egg reserve, and the OvaTureSM
treatment, a potential next-generation IVF treatment that could help a
woman produce healthy, young, fertilizable eggs without hormone
injections. For more information, please visit www.ovascience.com
and connect with us on Twitter
and Facebook.
Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment and its two fertility treatments in development. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to: our expectation that the AUGMENT treatment
and OvaPrime treatment meet the requirements of a class of products
exempt from premarket review and approval under applicable regulations
in those countries where we have launched or plan to introduce the
AUGMENT treatment and plan to introduce the OvaPrime treatment; the
science underlying our treatment and treatments in development
(including the AUGMENT, OvaPrime and OvaTure treatments), which is
unproven; our ability to obtain regulatory approval where necessary for
our potential treatments; our ability to develop our potential
treatments, including the OvaPrime and OvaTure treatments, on the
timelines we expect, if at all; our ability to commercialize the AUGMENT
treatment and our potential treatments, including the OvaPrime
treatment, on the timelines we expect, if at all; as well as those risks
more fully discussed in the “Risk Factors” section of our most recently
filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K.
The forward-looking statements contained in this press release reflect
our current views with respect to future events. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our
view as of any date subsequent to the date hereof.
###
Contacts:
Cara Petralia, 617-714-9638
Director, Corporate
Communications
cpetralia@ovascience.com